CagriSema vs Wegovy
Amylin + Semaglutide vs Semaglutide Alone (2026)
CagriSema is Novo Nordisk's next-generation combination — cagrilintide (an amylin analog) plus semaglutide — designed to go beyond what semaglutide does alone. Wegovy is semaglutide 2.4 mg, today's standard. Here's how the combination compares with the single agent it's built on.
CagriSema vs Wegovy: At a Glance
- ✓Cagrilintide (amylin analog) + semaglutide (GLP-1)
- ✓Once-weekly subcutaneous injection
- ✓Two complementary appetite mechanisms
- ✓REDEFINE 1: ~22.7% weight loss (on-treatment estimate)
- ✓NDA filed December 2025; FDA review in 2026
- ✓Novo Nordisk
- ✓Semaglutide — GLP-1 only
- ✓Once-weekly subcutaneous injection
- ✓FDA-approved and widely available
- ✓STEP-1: 14.9% weight loss at 68 weeks
- ✓SELECT: 20% cardiovascular risk reduction
- ✓Novo Nordisk
Detailed Comparison
| Feature | CagriSema | Wegovy (Semaglutide) |
|---|---|---|
| Components | Cagrilintide + semaglutide | Semaglutide 2.4 mgBest |
| Mechanism | Amylin + GLP-1 (dual pathway) | GLP-1 only |
| Manufacturer | Novo Nordisk | Novo Nordisk |
| Administration | Once-weekly injection | Once-weekly injection |
| Key Weight Loss | ~22.7% (REDEFINE 1, on-treatment) | 14.9% (STEP-1) |
| CV Outcome Data | Not yet established | SELECT: 20% MACE reduction |
| Status | Filed; FDA review 2026 | Approved (2021) |
| Availability | Not yet available | Widely available |
| Side Effects | GI effects (both pathways) | Nausea, vomiting, diarrhea |
How to Think About It
More Weight Loss
Adding cagrilintide (amylin) to semaglutide pushed REDEFINE 1 results well above semaglutide alone — roughly 22.7% vs 14.9%.
Available Now
Wegovy is the only one you can get today. CagriSema is filed with the FDA but not yet approved or on the market.
Proven Heart Benefit
Wegovy's SELECT trial showed a 20% reduction in cardiovascular events. CagriSema does not yet have that outcome data.
Two Mechanisms
CagriSema combines amylin and GLP-1 signaling — a different, additive approach to appetite than semaglutide's single pathway.
Tolerability
Both rely on appetite-pathway effects, so GI side effects are expected. Real-world tolerability of the combination is still emerging.
Built on Semaglutide
CagriSema literally contains semaglutide — so if you do well on Wegovy, the combination is an evolution, not a different drug class.
Which Should You Consider?
Right now this isn't a real choice: Wegovy is approved and available, and CagriSema is still under FDA review after a December 2025 filing. If you need treatment today, Wegovy is the option — with the added reassurance of SELECT cardiovascular outcome data.
CagriSema is the upgrade to watch. By adding cagrilintide (an amylin analog) to semaglutide, it reached roughly 22.7% weight loss in REDEFINE 1 — meaningfully above semaglutide alone. Because it contains semaglutide, it's best thought of as the next step in the same lineage rather than a different class.
If you do well on Wegovy now, that bodes well for the combination later. Track your dose, weight, and side effects in Shotlee so that if CagriSema becomes available, you have a clean baseline to judge whether the amylin add-on is worth switching for.
CagriSema vs Wegovy: Frequently Asked Questions
On weight loss, the data favors CagriSema: adding cagrilintide (amylin) to semaglutide produced roughly 22.7% in REDEFINE 1 versus 14.9% for semaglutide alone in STEP-1. But CagriSema isn't approved yet, and Wegovy has proven cardiovascular benefit.
Wegovy is semaglutide alone (GLP-1). CagriSema combines semaglutide with cagrilintide, an amylin analog, adding a second appetite-control pathway. Both are once-weekly Novo Nordisk injections.
Not yet. Novo Nordisk filed the FDA application in December 2025, with review expected in 2026. Wegovy is approved and available now.
Yes — CagriSema is cagrilintide plus semaglutide 2.4 mg. It builds on the same GLP-1 used in Wegovy and Ozempic, adding an amylin analog.
Yes. Shotlee tracks semaglutide and combination therapies — dose, weight, and side effects — so you can compare your results if you switch.
Track Wegovy or CagriSema in Shotlee
Free dose logging, weight trends, and side-effect tracking for any GLP-1 or combination therapy.